The application of the Integrated Discrete Multiple Organ Co-culture (IdMOC®) system in the evaluation of organ-specific toxicity is reviewed. In vitro approaches to predict in vivo toxicity have met with limited success, mainly because of the complexity of in vivo toxic responses. In vivo properties that are not well-represented in vitro include organ-specific responses, multiple organ metabolism, and multiple organ interactions. The IdMOC system has been developed to address these deficiencies. The system uses a ‘wells-within-a-well’ concept for the co-culturing of cells or tissue slices from different organs as physically separated (discrete) entities in the small inner wells. These inner wells are nevertheless interconnected (integrated) by overlying culture medium in the large outer containing well. The IdMOC system thereby models the in vivo situation, in which multiple organs are physically separated but interconnected by the systemic circulation, permitting multiple organ interactions. The IdMOC system, with either cells or tissue slices from multiple organs, can be used to evaluate cell type-specific or organ-specific toxicity.
OlingaP., MeijerK.F., SlooffM.J.H. & GroothuisG.M.M. (1998). Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue. Toxicology in Vitro12, 77–100.
2.
VickersA.E.M. (2009). Tissue slices for the evaluation of metabolism-based toxicity with the example of diclofenac. Chemico–Biological Interactions179, 9–16.
3.
LiA.P. & MyersC.A. (1988). In vitro evaluation of the cytotoxic potential of a novel man-made fiber, calcium sodium metaphosphate fiber (phosphate fiber). Fundamental & Applied Toxicology11, 21–28.
4.
LiA.P., LuC., BrentJ.A., PhamC., FackettA., RueggC.E. & SilberP.M. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chemico–Biological Interactions121, 17–35.
5.
DeldarA. & StevensC.E. (1993). Development and application of in vitro models of hematopoiesis to drug development. Toxicologic Pathology21, 231–240.
6.
DietrichD.R., O'BrienE., StackM.E. & HeussnerA.H. (2001). Species- and sex-specific renal cytotoxicity of ochratoxin A and B in vitro. Experimental & Toxicologic Pathology53, 215–225.
7.
GuizzettiM., PathakS., GiordanoG. & CostaL.G. (2005). Effect of organophosphorus insecticides and their metabolites on astroglial cell proliferation. Toxicology215, 182–190.
8.
HasinoffB.B., PatelD. & WuX. (2007). The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovascular Toxicology7, 19–27.
9.
HanS.G., CastranovaV. & VallyathanV. (2007). Comparative cytotoxicity of cadmium and mercury in a human bronchial epithelial cell line (BEAS-2B) and its role in oxidative stress and induction of heat shock protein 70. Journal of Toxicology & Environmental Health. Part A70, 852–860.
10.
GuillouzoA., CorluA., AninatC., GlaiseD., MorelF. & Guguen-GuillouzoC. (2007). The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico–Biological Interactions168, 66–73.
11.
CastellJ.V., JoverR., Martizez-JimenezC.P. & Gomez-LechonM.J. (2006). Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opinion on Drug Metabolism & Toxicology2, 183–212.
12.
ClemedsonC., DierickxP.J. & SjöströmM. (2003). The prediction of human acute systemic toxicity by the EDIT/MEIC in vitro test battery: the importance of protein binding and of partitioning into lipids. ATLA31, 245–256.
13.
GeretsH.H.J., CornetH.M., DepelchinD.O., CanningM. & AtienzarF.A. (2009). Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicology in Vitro23, 319–332.
14.
DambachD.M., AndrewsB.A. & MoulinF. (2005). New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicologic Pathology33, 17–26.
15.
LiA.P. (2001). Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today6, 357–366.
16.
LiA.P. (2004). In vitro approaches to evaluate ADMET drug properties. Current Topics in Medicinal Chemistry4, 701–706.
17.
LiA.P. (2005). Cell culture tool and method. US Patent 20050101010.
18.
LiA.P., BodeC. & SakaiY. (2004). A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chemico–Biological Interactions150, 129–136.
19.
LiA.P. (2008). In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology. ALTEX25, 43–49.
20.
LiA.P. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chemico–Biological Interactions142, 7–23.
21.
LiA.P. (2004). An integrated, multidisciplinary approach for drug safety assessment. Drug Discovery Today9, 687–693.
22.
LiA.P. (2007). Human-based in vitro experimental systems for the evaluation of human drug safety. Current Drug Safety2, 193–199.
23.
LiA.P. (2004). A comprehensive approach for drug safety assessment. Chemico–Biological Interactions150, 27–33.
24.
LiA.P. (2009). Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: Proof-of-concept study with aflatoxin B1. Chemico–Biological Interactions179, 4–8.
25.
LiuC.L., HuangJ.K., ChengS.P., ChangY.C., LeeJ.J. & LiuT.P. (2006). Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anti-cancer Drugs17, 709–713.
26.
McClayE.F., McClayM.T., MonroeL., JonesJ.A. & WinskiP.J. (2001). A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Research11, 309–313.
27.
LiA.P. (2009). Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metabolism & Disposition37, 1598–1603.
28.
BenowitzN.L. (2009). Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annual Review of Pharmacology & Toxicology49, 57–71.
